Anti-TACE [D1(A12)] rAb

Anti-TACE [D1 (A12)] is a human recombinant antibody. This antibody displays inhibitory behaviour to TNF-alpha converting enzyme (TACE). TACE is a membrane-bound metalloprotease (ADAM17) proved capable of cleaving a variety of pathologically significant substrates. TACE has emerged as an attractive therapeutic target for the treatment of cancer and rheumatoid arthritis._x000D_ _x000D_ D1(A12) binds a cross-domain […]

Contributors

Inventor Institute
Christopher Tape ; Gillian Murphy Cancer Research UK, Cambridge Institute, England
Cat. #: 152045
Tool sub type: Primary antibody
Unit size: 100 ug
Cancer types: Brain cancer, Lung cancer
Research Fields: Cancer;Cell signaling and signal transduction;Metabolism;Neurobiology;Stem cell biology
Application: Fn
Target: TACE (ADAM17)
Reactivity: Human
Clone: D1 (A12)
Host: Human
Class: Recombinant
Primary citation: Tape et al. 2011. Proc Natl Acad Sci U S A. 108(14):5578-5583. PMID: 21415364.
Alternate name: Anti-TACE [D1(A12)]
Product description: Anti-TACE [D1 (A12)] is a human recombinant antibody. This antibody displays inhibitory behaviour to TNF-alpha converting enzyme (TACE). TACE is a membrane-bound metalloprotease (ADAM17) proved capable of cleaving a variety of pathologically significant substrates. TACE has emerged as an attractive therapeutic target for the treatment of cancer and rheumatoid arthritis.  D1(A12) binds a cross-domain epitope. D1(A12) is the first ADAM inhibitor to show an affinity preference for the complete TACE ectodomain over the isolated catalytic domain.  This antibody is a selective TACE antagonist and provides a unique alternative to small molecule metalloprotease inhibition. This antibody allows the study of the individual pathological impact of TACE activity.
Conjugation: Biotin
Isotype: IgG1
Molecular weight: 93.02/ 91.12/ 68.22 kDa (prepro-/pro-/mature form) calculated
Immunogen: Recombinant human ADAM17 (TACE) ectodomain tagged to biotin.
Target background: TACE (CD156b) has proved capable of cleaving epidermal growth factor receptor (EGFR) ligands, extracellular Notch1, cell-surface receptors, and adhesion molecules. As proteolytic cleavage is an indispensable activation event for many of these substrates, TACE has emerged as an attractive therapeutic target for the treatment of cancer and rheumatoid arthritis. This cross-domain human antibody is a selective TACE antagonist and provides a unique alternative to smallmolecule meta…
Format: Liquid
Concentration: 5.9 mg/ml
Storage buffer: PBS
Storage conditions: -15° C to -25° C
Shipping conditions: Dry ice
References:

Caiazza et al. 2015. Br J Cancer. 112(12):1895-1903. PMID: 26010411.

Issuree et al. 2013. J Clin Invest. 123(2):928-932. PMID: 23348744.

Richards et al. 2012. PLoS One. 7(7):e40597. PMID: 22792380.

Tape et al. 2011. Proc Natl Acad Sci U S A. 108(14):5578-5583. PMID: 21415364.

Images

View Gallery
Cancer cells with known expression of TACE substrates (TOV21G

Related Tools for Antibodies

Cat. # Tool Name
151016 Anti-CyclinA [E72.1] Key Info View Tool
151027 Anti-HSVICP8 [10A3] Key Info View Tool
151033 Anti-HSVUL42 [13C9] Key Info View Tool
151036 Anti-ICAM1 [15.2] Key Info View Tool
151035 Anti-CD8 [14] mAb Key Info View Tool

Tool enquiry

Please ensure you use your organisation email address rather than personal where possible, as this helps us locate your organisation in our system faster.

Please note we may take up to three days to respond to your enquiry.

CancerTools.org uses the contact information provided to respond to you about our research tools and service. For more information please review our privacy policy.